NCT02776813View on ClinicalTrials.gov

Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

February 12, 2020

Study Completion Date

February 12, 2020

Conditions
Lymphoma
Interventions
BIOLOGICAL

ACTR087

BIOLOGICAL

rituximab

Trial Locations (7)

27710

Duke University Medical Center, Durham

43210

Ohio State University, Columbus

46237

Indiana Bone and Marrow Transplantation, Indianapolis

60153

Loyola University Chicago, Maywood

85234

Banner MD Anderson Cancer Center, Gilbert

06520

Yale University, New Haven

02114

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
lead

Cogent Biosciences, Inc.

INDUSTRY

NCT02776813 - Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma | Biotech Hunter | Biotech Hunter